Zafgen Insists Life For Beloranib After Patient Death
This article was originally published in Scrip
Executive Summary
Zafgen Inc. officials on Oct. 16 did their best to try to assure investors and analysts after the FDA slapped a partial hold on the company's Phase III bestPWS (ZAF-311) trial testing its experimental severe obesity drug beloranib following the death of one of the study participants taking the medicine – with the CEO even declaring the adverse outcome was "not an unexpected finding," given the firm anticipated one to two deaths would occur.